Headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3099000023737 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern’s scoring:
- Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.’s Q3 2017 Earnings (SPPI) (americanbankingnews.com)
- Jefferies Group LLC Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $18.00 (americanbankingnews.com)
- HC Wainwright Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $20.00 (americanbankingnews.com)
- Spectrum Pharmaceuticals, Inc. (SPPI) Downgraded to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
SPPI has been the topic of several research analyst reports. Jefferies Group LLC set a $9.00 target price on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Zacks Investment Research raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. HC Wainwright raised their target price on Spectrum Pharmaceuticals from $14.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. BidaskClub lowered Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, ValuEngine raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.75.
Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 13.67 on Thursday. The firm’s market cap is $1.07 billion. Spectrum Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $15.32. The firm’s 50-day moving average price is $11.15 and its 200 day moving average price is $8.13.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.01. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. The firm had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $30.50 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. Spectrum Pharmaceuticals’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, equities research analysts forecast that Spectrum Pharmaceuticals will post ($1.06) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/10/12/spectrum-pharmaceuticals-sppi-earning-somewhat-favorable-news-coverage-accern-reports.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
What are top analysts saying about Spectrum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectrum Pharmaceuticals Inc. and related companies.